Lipidomic Typing of Colorectal Cancer Tissue Containing Tumour-Infiltrating Lymphocytes by MALDI Mass Spectrometry Imaging.
MALDI-MSI
colorectal cancer
immunity
lipidomics
lymphocytes
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
05 Sep 2021
05 Sep 2021
Historique:
received:
23
07
2021
revised:
27
08
2021
accepted:
01
09
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
27
9
2021
Statut:
epublish
Résumé
Predicting the prognosis of colorectal cancer (CRC) patients remains challenging and a characterisation of the tumour immune environment represents one of the most crucial avenues when attempting to do so. For this reason, molecular approaches which are capable of classifying the immune environments associated with tumour infiltrating lymphocytes (TILs) are being readily investigated. In this proof of concept study, we aim to explore the feasibility of using spatial lipidomics by MALDI-MSI to distinguish CRC tissue based upon their TIL content. Formalin-fixed paraffin-embedded tissue from human thymus and tonsil was first analysed by MALDI-MSI to obtain a curated mass list from a pool of single positive T lymphocytes, whose putative identities were annotated using an LC-MS-based lipidomic approach. A CRC tissue microarray (TMA,
Identifiants
pubmed: 34564418
pii: metabo11090599
doi: 10.3390/metabo11090599
pmc: PMC8471593
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FAR 2017-2020
ID : FAR 2017-2020
Organisme : Fondazione Gigi & Pupa Ferrari Onlus
ID : Fondazione Gigi & Pupa Ferrari Onlus
Organisme : Regione Lombardia POR FESR 2014-2020
ID : Call HUB Ricerca ed Innovazione: ImmunHUB
Organisme : Regione Lombardia
ID : programma degli interventi per la ripresa economica: sviluppo di nuovi accordi di collabora-zione con le università per la ricerca, l'innovazione e il trasferimento tecnologico
Références
Arch Pathol Lab Med. 2016 Sep;140(9):893-8
pubmed: 27575264
Gastroenterology. 2020 Aug;159(2):453-466.e1
pubmed: 32417404
Mass Spectrom Rev. 2018 Mar;37(2):107-138
pubmed: 27276657
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Treat Rev. 2019 Jun;76:22-32
pubmed: 31079031
Metabolites. 2021 Aug 26;11(9):
pubmed: 34564393
Oncogenesis. 2020 Jul 9;9(7):66
pubmed: 32647253
J Am Soc Mass Spectrom. 2020 Aug 5;31(8):1619-1624
pubmed: 32678590
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Oncoimmunology. 2020 Jul 11;9(1):1789032
pubmed: 32934885
JCO Precis Oncol. 2018 Nov;2:1-15
pubmed: 35135158
J Pathol. 2015 Sep;237(1):123-32
pubmed: 25965788
Br J Cancer. 2019 Oct;121(8):659-665
pubmed: 31488881
J Proteomics. 2019 Jan 16;191:114-123
pubmed: 29581064
Oncoimmunology. 2019 Apr 3;8(7):1593806
pubmed: 31143514
Nat Cell Biol. 2005 Aug;7(8):808-16
pubmed: 16025105
NPJ Precis Oncol. 2021 Mar 8;5(1):18
pubmed: 33686176
Adv Drug Deliv Rev. 2020;159:245-293
pubmed: 32711004
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
Cancers (Basel). 2020 Dec 20;12(12):
pubmed: 33419310
Lipids Health Dis. 2019 Jan 26;18(1):29
pubmed: 30684960
J Immunol. 2011 Mar 15;186(6):3299-303
pubmed: 21317389
J Histochem Cytochem. 2017 Aug;65(8):431-444
pubmed: 28692376
J Mass Spectrom. 2020 Apr;55(4):e4491
pubmed: 31860760
Front Immunol. 2019 Apr 11;10:700
pubmed: 31031745
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
Sci Rep. 2020 Feb 25;10(1):3360
pubmed: 32099066
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Mol Oncol. 2014 Feb;8(1):39-49
pubmed: 24112879
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Mar;1865(3):158579
pubmed: 31794862
Cell. 2019 May 2;177(4):1035-1049.e19
pubmed: 31031003
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13
pubmed: 30581539
Oncotarget. 2016 Jul 12;7(28):44288-44298
pubmed: 27329588
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419